Although there is no established phenotype in T2DM concerning SGLT-2 inhibitor-associated eDKA, it appears that patients with a longer history of diabetes, poorer control of disease, lower BMI, and poorer β cell function reserve are more susceptible to eDKA. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.